Dean F. Bajorin, MD, and Peter H. O’Donnell, MD, on Urothelial Cancer: Results From Two KEYNOTE Trials

2017 ASCO Annual Meeting
Tweet this page

Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, and Peter H. O’Donnell, MD, of The University of Chicago Medical Center, discuss their study findings on treating advanced urothelial cancer with pembrolizumab, paclitaxel, docetaxel, or vinflunine. (Abstracts 4501 and 4502)

Advertisement

Advertisement



Advertisement